Illumina, Inc. (NASDAQ:ILMN) Given Consensus Rating of “Hold” by Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given an average recommendation of “Hold” by the eighteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $137.75.

Several equities analysts have weighed in on the company. Citigroup lifted their price objective on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Guggenheim lifted their price objective on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. Weiss Ratings cut Illumina from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. JPMorgan Chase & Co. lifted their price objective on Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Finally, Stifel Nicolaus lifted their price objective on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, January 20th.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $142.54 on Friday. The stock has a market capitalization of $21.57 billion, a PE ratio of 25.92, a P/E/G ratio of 2.36 and a beta of 1.42. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The business has a fifty day moving average price of $128.58 and a two-hundred day moving average price of $129.52. Illumina has a fifty-two week low of $78.55 and a fifty-two week high of $155.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts predict that Illumina will post 5.2 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Keith A. Meister sold 225,067 shares of Illumina stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $145.55, for a total value of $32,758,501.85. Following the transaction, the director owned 3,604,441 shares in the company, valued at approximately $524,626,387.55. This trade represents a 5.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Christensen Jakob Wedel sold 700 shares of Illumina stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the transaction, the senior vice president owned 15,056 shares in the company, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 332,530 shares of company stock worth $48,303,655. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Illumina

Several hedge funds and other institutional investors have recently modified their holdings of ILMN. Capital World Investors increased its stake in shares of Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after purchasing an additional 3,331,542 shares during the last quarter. WCM Investment Management LLC increased its stake in shares of Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Invesco Ltd. increased its stake in shares of Illumina by 97.0% in the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after purchasing an additional 1,352,731 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Finally, Morgan Stanley increased its stake in shares of Illumina by 66.0% in the 4th quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after purchasing an additional 1,005,474 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.